The crystal packing and slip plane analysis in mechanical properties improvement of mefenamic acid by cocrystallization with nicotinamide coformer
Article Sidebar
Main Article Content
Abstract
Mefenamic acid is an analgesic non-steroidal anti-inflammatory drug (NSAID) that is categorized as Biopharmaceutical Classification System (BCS) class II drug. Cocrystallization of mefenamic acid (MFA) with nicotinamide (NIC) has been reported to enhance the solubility of MFA for about 2.56 times higher than pure MFA. As a part of MFA-NIC development in pharmaceutical dosage form, we reported the improvement of mechanical properties of MFA-NIC cocrystal based on the presence of slip planes in crystal structure. The research was initially by synthesizing and characterizing the cocrystal by using X-ray diffraction analysis, and was followed by the investigation of the mechanical properties of MFA and its cocrystal, i.e. tensile strength and deformation parameter. The correlation of crystal structure with mechanical properties was determined by crystal packing motif and slip plane analysis from single crystal data by using Mercury 3.6. The tensile strength of MFA was acceptance at 20.0 MPa, and dropped at more than 25.0 MPa. A better tableting performance was observed in MFA-NIC cocrystal which had the tensile strength 1.5 times higher than MFA at 12.5 MPa and gradually increased with an increasing pressure up to 2.5 times at 22.5 MPa. The flat slip plane of MFA-NIC cocrystal was predicted as the key factor in the improvement of its mechanical properties, compared to zigzag slip plane of MFA. In conclusion, MFA-NIC cocrystal had the better mechanical properties than pure MFA due to its flat slip plane and it becomes potential to be explored in further development of solid dosage form.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
Open Access authors retain the copyrights of their papers, and all open access articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
2. T. Ranjit, A. Delori, W. Jones, M. P. Lipert, L. Roy and N. Rodriguez-Hornedo, Pharmaceutical cocrystal and poorly soluble drugs, Int. J. Pharm. (2013) 1-24.
3. N. Blagden, D. Matas, M. Gavan, P. T., York, P, Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates, Adv. Drug. Deliv. Rev. (2007) 617-30.
4. D.D. Gadade and S.S. Pekamwar, Pharmaceutical cocrystals: Regulatory and strategic aspects, design and development, Adv. Pharm. Bull. (2016) 479-494.
5. Nijhawan, A. Monika, P. R. Santhosh, B. Sathesh and C.V.S. Subrahmanyam., Solid state manipulation of lornoxicam for cocrystal-physicochemical characterization, Drug Dev. Ind. Pharm. (2013) 1-10.
6. Patole, Tanvee and D. Ashwini, Co-crystallization a technique for solubility enhancement, Int. J. Pharm. Sci. Res. (2014) 3566-3576.
7. S. Emami, M. S. Shadbad, K. Adibkia. M. B. Jalali, Recent advances in improving oral drug bioavailability by cocrystals, Bioimpacts. (2018) 305-320.
8. Z. Rahman, C. Agarabi, A. S. Zidan, S. R. Khan, A.M. Khan, Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide, AAPS Pharm. Sci. Tech. (2011) 693-704.
9. D. Setyawan, A. Paramanandana, V. E. Erfadrin, R. Sari, D.P. Paramita, Compression force effect on characteristics of loratadine-succinic acid cocrystal prepared by slurry method, J Res. Pharm. (2020) 410-414.
10. A. V. Trask, W. D. Motherwell, W. Jones, Physical stability enhancement of theophylline via cocrystallization, Int. J. Pharm (2006) 114–123.
11. O. D. Putra, D. Umeda, Y. P. Nugraha, T. Furuishi, H. Nagase, K. Fukuzawa, H. Uekusa, E. Yonemochi, Solubility improvement of epalrestat by lapisaned structure formation via cocrystallization, Cryst. Eng. Comm (2017) 2614–2622.
12. P. Shanpui, N. R. Gound, U. B. R. Khandavilli, A. Nangia, Fast dissolving curcumin cocrystal. Cryst. Growth. Des (2011) 4135-4145.
13. P. P. Bag, M. Chen, C. C. Sun, C. M. Reddy, Direct correlation among crystal structure, mechanical behaviour and tabletability in a trimorphic molecular compound, Cryst. Eng. Comm. (2012) 3865–3867.
14. C. C. Sun and Y. H. Kiang., On the identification of slip planes in organic crystals based on attachment energy calculation, J. Pharm. Sci. (2008) 3456–3461.
15. C. C. Sun, D. J. W. Grant, Influence of crystal structure on the tableting properties of sulfamerazine polymorphs, Pharm. Res. (2001) 274–280.
16. C. C. Sun CC, H. Hou, Improving mechanical properties of caffeine and methyl gallate crystals by cocrystallization, Cryst. Growth. Des (2008) 1575–1579.
17. C. C. Sun, D. J. W. Grant, Improved tableting properties of phydroxybenzoic acid by water of crystallization: A molecular insight, Pharm. Res (2004) 382–386.
18. Y. Feng, D. J. W. Grant, Influence of crystal structure on the compaction properties of n-alkyl 4-hydroxybenzoate esters (parabens), Pharm. Res. (2006) 1608–1616.
19. K. S. Khomane P. K. More, G. Raghavendra A. K. Bansal, Molecular understanding of the compaction behaviour of indomethacin polymorphs, Mol. Pharm. (2013) 631–639.
20. P. Upadhyay, K.S. Khomane L. Kumar, A. K. Bansal, Relationship between crystal structure and mechanical properties of ranitidine hydrochloride polymorphs, Cryst. Eng. Comm (2013) 3959–3964.
21. D. P. Kale, V. Puri. A. Kumar and A. K. Bansal, The role of crystallization-mediated altered crystallographic properties on the tableability of rivaroxaban and malonic acid, Pharmaceutics. (2020) 546-568.
22. A. B. Bani-Jaber, I. Hamdan. B. Al-Khaidi, Sodium mefenamate as a solution for the problems of mefenamic acid formulation and dissolution, Chem. Pharm. Bull. (2007) 1136 – 1140.
23. L. Fabian, N. Hamill, K. S. Eccles, R. Moynihan, L. McCausland S. E. Lawrence et al., Cocrystal of fenamic acids with nicotinamide, Cryst. Growth. Des. (2011) 3522-3528.
24. D. Utami, I. Nugrahani, S. Ibrahim, Mefenamic acid-nicotinamide co-crystal synthesized by using melt crystallization method and its solubility study, Asian Journal of Pharmaceutical and Clinical Research. (2016) 135 – 139.
25. G. Alderborn, C. Nystrom, Pharmaceutical powder compaction technology, 1st edition, New York, Marcel Dekker, 377.
26. O. A. Saputra, Kurnia, S. Pujiasih, V. N. Rizki, B. Nurhayati, E. Pramono and C. Purnawan, Silylated-montmorillonite as co-adsorbent of chitosan composites for methylene blue dye removal in aqueous solution, Commun. Sci. Technol. (2020) 45-52.
27. E. Taer, L. Pratiwi, A. Apriwandi, W. S. Mustika, R. Taslim and A. Agustino, Three-dimensional pore structure of activated carbon monolithic derived from hierarchically bamboo stem for supercapacitor application, Communications in Science and Technology. (2020) 22-30.
28. S. Grangeon, F. Claret, Y. Linard, C. Chiabaerge, X-ray diffraction: a powerful tool to probe and understand the structure of nanocrystalline calcium silicate hydrates. Acta. Cryst. (2013) 465-473.
29. H. Ahmed, M. R. Shimpi, S. P. Velaga, Relationship between mechanical properties and crystal structure in cocrystal and salt o paracetamol, Drug Dev. Ind. Pharm. (2016) 89-97.
30. M. H. Shariare, F. J. J. Leusen, M. D. Matas, P. York, J. Anwar, Prediction of the mechanical behaviour of crystalline solids, Pharm. Res. (2011) 319-331.